Recent applications of cell-penetrating peptide guidance of nanosystems in breast and prostate cancer (Review)
- Authors:
- Samuel Longoria-García
- Celia Nohemi Sánchez-Domínguez
- Hugo Leonid Gallardo-Blanco
-
Affiliations: Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo Leon, Monterrey, Nuevo León 64460, Mexico, Department of Genetics, University Hospital ‘José Eleuterio González’, Autonomous University of Nuevo Leon, Monterrey, Nuevo León 64460, Mexico - Published online on: February 1, 2022 https://doi.org/10.3892/ol.2022.13223
- Article Number: 103
-
Copyright: © Longoria-García et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Parsa Y, Mirmalek SA, Kani FE, Aidun A, Salimi-Tabatabaee SA, Yadollah-Damavandi S, Jangholi E, Parsa T and Shahverdi E: A review of the clinical implications of breast cancer biology. Electron Physician. 8:2416–2424. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu D, Si M, Xue HY and Wong HL: Nanomedicine applications in the treatment of breast cancer: Current state of the art. Int J Nanomedicine. 12:5879–5892. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E and Lin SH: Molecular classification of prostate cancer progression: Foundation for marker-driven treatment of prostate cancer. Cancer Discov. 3:849–861. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang A, Zhang J, Plymate S and Mostaghel EA: Classical and Non-classical roles for pre-receptor control of DHT metabolism in prostate cancer progression. Horm Cancer. 7:104–113. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu LL, Xie N, Sun S, Plymate S, Mostaghel E and Dong X: Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 33:3140–3150. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Culig Z and Santer FR: Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 33:413–427. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rebello RJ, Pearson RB, Hannan RD and Furic L: Therapeutic approaches targeting MYC-Driven prostate cancer. Genes (Basel). 8:712017. View Article : Google Scholar : PubMed/NCBI | |
|
Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, Dugdale J, Kuehn E, Kohli M, Jimenez R, et al: TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer. Clin Cancer Res. 24:4551–4565. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Nadal M, Prekovic S, Gallastegui N, Helsen C, Abella M, Zielinska K, Gay M, Vilaseca M, Taulès M, Houtsmuller AB, et al: Structure of the homodimeric androgen receptor ligand-binding domain. Nat Commun. 8:143882017. View Article : Google Scholar : PubMed/NCBI | |
|
Damyanov CA, Maslev IK and Pavlov VS: Conventional treatment of cancer realities and problems. Ann Complement Altern Med. 1:1–9. 2018. | |
|
Schaue D and Mcbride WH: Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 12:527–540. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Estanqueiro M, Amaral MH, Conceição J and Sousa Lobo JM: Nanotechnological carriers for cancer chemotherapy: The state of the art. Colloids Surfaces B Biointerfaces. 126:631–648. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vanneman M and Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 12:237–251. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gao QX, Zhou GX, Lin SJ, Paus R and Yue ZC: How chemotherapy and radiotherapy damage the tissue: Comparative biology lessons from feather and hair models. Exp Dermatol. 28:413–418. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shi J, Kantoff PW, Wooster R and Farokhzad OC: Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer. 17:20–37. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi K, Ono K, Suzuki H, Sawada M, Moriya M, Sakamoto W and Yogo T: High-frequency, magnetic-field-responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect. ACS Appl Mater Interfaces. 2:1903–1911. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kong SD, Zhang W, Lee JH, Brammer K, Lal R, Karin M and Jin S: Magnetically vectored nanocapsules for tumor penetration and remotely switchable on-demand drug release. Nano Lett. 10:5088–5092. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tang B, Zaro JL, Shen Y, Chen Q, Yu Y, Sun P, Wang Y, Shen WC, Tu J and Sun C: Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting. J Control Release. 279:147–156. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Q, Song L, Chen S, Gao J, Zhao P and Du J: A superparamagnetic polymersome with extremely high T2 relaxivity for MRI and cancer-targeted drug delivery. Biomaterials. 114:23–33. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ke W, Li J, Mohammed F, Wang Y, Tou K, Liu X, Wen P, Kinoh H, Anraku Y, Chen H, et al: Therapeutic polymersome nanoreactors with tumor-specific activable cascade reactions for cooperative cancer therapy. ACS Nano. 13:2357–2369. 2019.PubMed/NCBI | |
|
Gao X, Wang S, Wang BL, Deng S, Liu X, Zhang XN, Luo LL, Fan RR, Xiang ML, You C, et al: Improving the anti-ovarian cancer activity of docetaxel with biodegradable self-assembly micelles through various evaluations. Biomaterials. 53:646–658. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mao HL, Qian F, Li S, Shen JW, Ye CK, Hua L, Zhang LZ, Wu DM, Lu J, Yu RT, et al: Delivery of doxorubicin from hyaluronic acid-modified glutathione-responsive ferrocene micelles for combination cancer therapy. Mol Pharm. 16:987–994. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Tan S, Li S, Shen Q and Wang K: Cancer drug delivery in the nano era: An overview and perspectives (Review). Oncol Rep. 38:611–624. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zariwala MG, Bendre H, Markiv A, Farnaud S, Renshaw D, Taylor KM and Somavarapu S: Hydrophobically modified chitosan nanoliposomes for intestinal drug delivery. Int J Nanomedicine. 13:5837–5848. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Liu X, Cai Z, Zhang H, Gao H, He W, Wu P, Cai C, Zhu JJ and Yan Z: Enhancing the plasmon resonance absorption of multibranched gold nanoparticles in the near-infrared region for photothermal cancer therapy: Theoretical predictions and experimental verification. Chem Mater. 31:471–482. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bellassai N, D'Agata R, Jungbluth V and Spoto G: Surface plasmon resonance for biomarker detection: Advances in Non-invasive cancer diagnosis. Front Chem. 7:5702019. View Article : Google Scholar : PubMed/NCBI | |
|
Kishimoto TK, Ferrari JD, Lamothe RA, Kolte PN, Griset AP, O'Neil C, Chan V, Browning E, Chalishazar A, Kuhlman W, et al: Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat Nanotechnol. 11:890–899. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Böhmová E, Machová D, Pechar M, Pola R, Venclíková K, Janoušková O and Etrych T: Cell-penetrating peptides: A useful tool for the delivery of various cargoes into cells. Physiol Res. 67 (Suppl 2):S267–S279. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kauffman WB, Fuselier T, He J and Wimley WC: Mechanism matters: A taxonomy of cell penetrating peptides. Trends Biochem Sci. 40:749–764. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Frankel AD and Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55:1189–1193. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Green M and Loewenstein PM: Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 55:1179–1188. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Bechara C and Sagan S: Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 587:1693–1702. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Guidotti G, Brambilla L and Rossi D: Cell-penetrating peptides: From basic research to clinics. Trends Pharmacol Sci. 38:406–424. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Huang K and García AE: Free energy of translocating an arginine-rich cell-penetrating peptide across a lipid bilayer suggests pore formation. Biophys J. 104:412–420. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Herce HD, Garcia AE, Litt J, Kane RS, Martin P, Enrique N, Rebolledo A and Milesi V: Arginine-rich peptides destabilize the plasma membrane, consistent with a pore formation translocation mechanism of cell-penetrating peptides. Biophys J. 97:1917–1925. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Islam MZ, Ariyama H, Alam JM and Yamazaki M: Entry of cell-penetrating peptide transportan 10 into a single vesicle by translocating across lipid membrane and its induced pores. Biochemistry. 53:386–396. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sharmin S, Islam MZ, Karal MAS, Alam Shibly SU, Dohra H and Yamazaki M: Effects of lipid composition on the entry of cell-penetrating peptide oligoarginine into single vesicles. Biochemistry. 55:4154–4165. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lindgren M and Langel U: Classes and prediction of cell-penetrating peptides. Methods in molec8ular biology (Clifton N.J.). 683:3–19. 2011.PubMed/NCBI | |
|
Cai D, Gao W, He B, Dai W, Zhang H, Wang X, Wang J, Zhang X and Zhang Q: Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials. 35:2283–2294. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z and Mei X: PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy. Biomaterials. 35:4368–4381. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Morshed RA, Muroski ME, Dai Q, Wegscheid ML, Auffinger B, Yu D, Han Y, Zhang L, Wu M, Cheng Y and Lesniak MS: Cell-penetrating peptide-modified gold nanoparticles for the delivery of doxorubicin to brain metastatic breast cancer. Mol Pharm. 13:1843–1854. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu X, Xu Y, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, et al: Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci. 112:7779–7784. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Parvani JG, Gujrati MD, Mack MA, Schiemann WP and Lu ZR: Silencing β3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer. Cancer Res. 75:2316–2325. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vaidya AM, Sun Z, Ayat N, Schilb A, Liu X, Jiang H, Sun D, Scheidt J, Qian V, He S, et al: Systemic delivery of tumor-targeting siRNA Nanoparticles against an oncogenic LncRNA facilitates effective triple-negative breast cancer therapy. Bioconjug Chem. 30:907–919. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pasut G, Paolino D, Celia C, Mero A, Joseph AS, Wolfram J, Cosco D, Schiavon O, Shen H and Fresta M: Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. J Control Release. 199:106–113. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nag M, Gajbhiye V, Kesharwani P and Jain NK: Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells. Colloids Surfaces B Biointerfaces. 148:363–370. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ebbesen MF, Olesen MTJ, Gjelstrup MC, Pakula MM, Larsen EKU, Hansen IM, Hansen PL, Mollenhauer J, Malle BM and Howard KA: Tunable CD44-specific cellular retargeting with hyaluronic acid nanoshells. Pharm Res. 32:1462–1474. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong L, Xu L, Liu Y, Li Q, Zhao D, Li Z, Zhang H, Zhang H, Kan Q, Wang Y, et al: Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy. Acta Pharm Sin B. 9:397–409. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ben Djemaa S, David S, Hervé-Aubert K, Falanga A, Galdiero S, Allard-Vannier E, Chourpa I and Munnier E: Formulation and in vitro evaluation of a siRNA delivery nanosystem decorated with gH625 peptide for triple negative breast cancer theranosis. Eur J Pharm Biopharm. 131:99–108. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mäe M, Myrberg H, El-Andaloussi S and Langel Ü: Design of a tumor homing cell-penetrating peptide for drug delivery. Int J Pept Res Ther. 15:11–15. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lim KJ, Sung BH, Shin JR, Lee YW, Kim DJ, Yang KS and Kim SC: A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS One. 8:e660842013. View Article : Google Scholar : PubMed/NCBI | |
|
Fang SL, Fan TC, Fu HW, Chen CJ, Hwang CS, Hung TJ, Lin LY and Chang MD: A novel cell-penetrating peptide derived from human eosinophil cationic protein. PLoS One. 8:e573182013. View Article : Google Scholar : PubMed/NCBI | |
|
Kalyanaraman B: Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biol. 29:1013942020. View Article : Google Scholar : PubMed/NCBI | |
|
Fales AM, Yuan H and Vo-Dinh T: Cell-penetrating peptide enhanced intracellular Raman imaging and photodynamic therapy. Mol Pharm. 10:2291–2298. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hossain MK, Cho HY, Kim KJ and Choi JW: In situ monitoring of doxorubicin release from biohybrid nanoparticles modified with antibody and cell-penetrating peptides in breast cancer cells using surface-enhanced Raman spectroscopy. Biosens Bioelectron. 71:300–305. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wan Y, Dai W, Nevagi RJ, Toth I and Moyle PM: Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells. Acta Biomater. 59:257–268. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hu G, Chun X, Wang Y, He Q and Gao H: Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment. Oncotarget. 6:41258–41274. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sardan M, Kilinc M, Genc R, Tekinay AB and Guler MO: Cell penetrating peptide amphiphile integrated liposomal systems for enhanced delivery of anticancer drugs to tumor cells. Faraday Discuss. 166:269–283. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Chen X, Yang X, Gao W, He B, Dai W, Zhang H, Wang X, Wang J, Zhang X, et al: A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer. Nanomedicine. 12:387–397. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Wang H, Liang J, Jiang Y, Guo Q, Peng H, Xu Q and Huang Y: Cell-penetrating apoptotic peptide/p53 DNA nanocomplex as adjuvant therapy for drug-resistant breast cancer. Mol Pharm. 11:3352–3360. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Li S and Shen Q: Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery. Eur J Pharm Sci. 47:430–443. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hu H, Wang J, Wang H, Tan T, Li J, Wang Z, Sun K, Li Y and Zhang Z: Cell-penetrating peptide-based nanovehicles potentiate lymph metastasis targeting and deep penetration for anti-metastasis therapy. Theranostics. 8:3597–3610. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cabral H, Makino J, Matsumoto Y, Mi P, Wu H, Nomoto T, Toh K, Yamada N, Higuchi Y, Konishi S, et al: Systemic targeting of lymph node metastasis through the blood vascular system by using size-controlled nanocarriers. ACS Nano. 9:4957–4967. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kang S, Ahn S, Lee J, Kim JY, Choi M, Gujrati V, Kim H, Kim J, Shin EC and Jon S: Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. J Control Release. 256:56–67. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Su J, Sun H, Meng Q, Yin Q, Tang S, Zhang P, Chen Y, Zhang Z, Yu H and Li Y: Long circulation red-blood-cell-mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer. Adv Funct Mater. 26:1243–1252. 2016. View Article : Google Scholar | |
|
Hamilton AM, Aidoudi-Ahmed S, Sharma S, Kotamraju VR, Foster PJ, Sugahara KN, Ruoslahti E and Rutt BK: Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. J Mol Med. 93:991–1001. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jabir MS, Taha AA, Sahib UI, Taqi ZJ, Al-Shammari AM and Salman AS: Novel of nano delivery system for Linalool loaded on gold nanoparticles conjugated with CALNN peptide for application in drug uptake and induction of cell death on breast cancer cell line. Mater Sci Eng C Mater Biol Appl. 94:949–964. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wan X, Liu C, Lin Y, Fu J, Lu G and Lu Z: pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer. Drug Deliv. 26:470–480. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liang DS, Su HT, Liu YJ, Wang AT and Qi XR: Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-α-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers. Biomaterials. 71:11–23. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ding J, Yao J, Xue J, Li R, Bao B, Jiang L, Zhu JJ and He Z: Tumor-homing Cell-penetrating peptide linked to colloidal mesoporous silica Encapsulated (-)-Epigallocatechin-3-gallate as drug delivery system for breast cancer therapy in vivo. ACS Appl Mater Interfaces. 7:18145–18155. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ding J, Liang T, Zhou Y, He Z, Min Q, Jiang L and Zhu J: Hyaluronidase-triggered anticancer drug and siRNA delivery from cascaded targeting nanoparticles for drug-resistant breast cancer therapy. Nano Res. 10:690–703. 2016. View Article : Google Scholar | |
|
Ding J, Liang T, Min Q, Jiang L and Zhu JJ: ‘Stealth and Fully-Laden’ Drug carriers: Self-assembled nanogels encapsulated with epigallocatechin gallate and siRNA for drug-resistant breast cancer therapy. ACS Appl Mater Interfaces. 10:9938–9948. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Huang R, Li J, Kebebe D, Wu Y, Zhang B and Liu Z: Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment. Drug Deliv. 25:757–765. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Perillo E, Hervé-Aubert K, Allard-Vannier E, Falanga A, Galdiero S and Chourpa I: Synthesis and in vitro evaluation of fluorescent and magnetic nanoparticles functionalized with a cell penetrating peptide for cancer theranosis. J Colloid Interface Sci. 499:209–217. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cao H, Zou L, He B, Zeng L, Huang Y, Yu H, Zhang P, Yin Q, Zhang Z and Li Y: Albumin biomimetic nanocorona improves tumor targeting and penetration for synergistic therapy of metastatic breast cancer. Adv Funct Mater. 27:16056792017. View Article : Google Scholar | |
|
Jing H, Cheng W, Li S, Wu B, Leng X, Xu S and Tian J: Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy. Colloids Surfaces B Biointerfaces. 146:387–395. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Govindarajan S, Sivakumar J, Garimidi P, Rangaraj N, Kumar JM, Rao NM and Gopal V: Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate. Biomaterials. 33:2570–2582. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma S, Kotamraju VR, Mölder T, Tobi A, Teesalu T and Ruoslahti E: Tumor-penetrating nanosystem strongly suppresses breast tumor growth. Nano Lett. 17:1356–1364. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li G, Gao Y, Gong C, Han Z, Qiang L, Tai Z, Tian J and Gao S: Dual-blockade immune checkpoint for breast cancer treatment based on a tumor-penetrating peptide assembling nanoparticle. ACS Appl Mater Interfaces. 11:39513–39524. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xie X, Yang Y, Lin W, Liu H, Liu H, Yang Y, Chen Y, Fu X and Deng J: Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery. Colloids Surfaces B Biointerfaces. 136:641–650. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Braun GB, Sugahara KN, Yu OM, Kotamraju VR, Mölder T, Lowy AM, Ruoslahti E and Teesalu T: Urokinase-controlled tumor penetrating peptide. J Control Release. 232:188–195. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fei L, Yap LP, Conti PS, Shen WC and Zaro JL: Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide. Biomaterials. 35:4082–4087. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lang J, Zhao X, Qi Y, Zhang Y, Han X, Ding Y, Guan J, Ji T, Zhao Y and Nie G: Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. ACS Nano. 13:12357–12371. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang B, Dong DW, Shi NQ, Gao W, Yang ZZ, Cui Y, Cao DY and Qi XR: PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials. 34:6976–6991. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Fan J and Hsieh JT: Inhibition of mitogen-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle. Cancer Res. 66:8954–8958. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang T, Xue X, He D and Hsieh JT: A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA. Cancer Lett. 365:156–165. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar A, Huo S, Zhang X, Liu J, Tan A, Li S, Jin S, Xue X, Zhao Y, Ji T, et al: Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of Platinum(IV) drug for prostate cancer treatment. ACS Nano. 8:4205–4220. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Menon JU, Tumati V, Hsieh JT, Nguyen KT and Saha D: Polymeric nanoparticles for targeted radiosensitization of prostate cancer cells. J Biomed Mater Res A. 103:1632–1639. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wadajkar AS, Menon JU, Tsai YS, Gore C, Dobin T, Gandee L, Kangasniemi K, Takahashi M, Manandhar B, Ahn JM, et al: Prostate cancer-specific thermo-responsive polymer-coated iron oxide nanoparticles. Biomaterials. 34:3618–3625. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan L, Liu CY, Chen Y, Zhang ZH, Zhou L and Qu D: Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model. Int J Nanomedicine. 8:4339–4350. 2013.PubMed/NCBI | |
|
Jiménez-Mancilla N, Ferro-Flores G, Santos-Cuevas C, Ocampo-García B, Luna-Gutiérrez M, Azorín-Vega E, Isaac-Olivé K, Camacho-López M and Torres-García E: Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49–57)-Lys(3)-bombesin internalized in nuclei of prostate cancer cells. J Label Compd Radiopharm. 56:663–671. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
DePorter SM and McNaughton BR: Engineered M13 bacteriophage nanocarriers for intracellular delivery of exogenous proteins to human prostate cancer cells. Bioconjug Chem. 25:1620–1625. 2014. View Article : Google Scholar : PubMed/NCBI |
